Search

Displaying results 4531 - 4540 of 5897 in total
  1. Drug

    PF-06751979

    go.drugbank.com/drugs/DB15105
    Investigational

    PF-06751979 is under investigation in clinical trial NCT03126721 (The Study is to Evaluate the Effect of Multiple Doses PF-06751979 on the Pharmacokinetics of Midazolam in Healthy Adults).

  2. Drug

    Efmarodocokin alfa

    go.drugbank.com/drugs/DB16398
    Investigational

    Efmarodocokin alfa is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).

    Synonyms: HUMAN INTERLEUKIN 22 (1-146), FUSED TO HUMAN IMMUNOGLOBULIN HEAVY CONSTANT GAMMA 4 (CH1(97-98), H(S10>P(158)), CH2(N67>G(227)))-(147-377), DIMER (156-156':159-159')-BISDISULFIDE, PRODUCED IN CHO CELLS,
  3. Drug

    Anzurstobart

    go.drugbank.com/drugs/DB17547
    Investigational

    Anzurstobart is a monoclonal antibody directed against signal-regulatory protein alpha (SIRPα) on monocytes and macrophages to potently block the CD47-SIRPα interaction.

  4. Drug

    Benapenem

    go.drugbank.com/drugs/DB18883
    Investigational

    Benapenem is under investigation in clinical trial NCT04505683 (A Study to Assess Efficacy and Safety Intravenous Benapenem in Patients With Complicated Urinary Tract Infection (Cuti) or Acute Pyelonephritis

  5. Drug

    Minzasolmin

    go.drugbank.com/drugs/DB18961
    Investigational

    Minzasolmin is under investigation in clinical trial NCT05543252 (An Extension Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's

  6. Drug

    Recombinant human kallikrein-1

    go.drugbank.com/drugs/DB19232
    Investigational

    Recombinant human kallikrein-1 is under investigation in clinical trial NCT01845064 (A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients).

  7. Drug

    Ulevostinag

    go.drugbank.com/drugs/DB14721
    Investigational

    Upon intratumoral (IT) administration, STING agonist MK-1454 binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear … factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment; this leads to the production of pro-inflammatory cytokines, including interferons (IFNs)

    Synonyms: Guanosine, (p(r))-2'-deoxy-2'-fluoro-5'-o-((r)-hydroxymercaptophosphinyl)-p-thio-.beta.-d-arabino-adenylyl-(3'->5')-3'-deoxy-3'-fluoro-, cyclic nucleotide
  8. Drug

    CoVac-1

    go.drugbank.com/drugs/DB16429
    Investigational

    It is being investigated in the clinical trial NCT04546841 (Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults (pVAC))[L30428] and aims to induce broad

  9. Drug

    Liposomal prostaglandin E1

    go.drugbank.com/drugs/DB05391
    Investigational

    Liposome-encapsulated form of prostaglandin E1 (Liprostin) is known to be a potent vasodilator and platelet inhibitor as well as an anti-inflammatory and anti-thrombotic agent.

  10. Drug

    Brecanavir

    go.drugbank.com/drugs/DB04887
    Investigational

    In July 2006, Vertex indicated that it expected GSK to initiate phase III trials of the drug in 2007. … In December of 2006 GSK announced a decision to discontinue the development of brecanavir for the treatment of HIV. The decision was based on issues regarding the formulation of the drug.